{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:49:00Z","timestamp":1761396540336,"version":"3.37.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1 R03 CA241788-01A1","1 R03 CA241788-01A1"],"award-info":[{"award-number":["1 R03 CA241788-01A1","1 R03 CA241788-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00520-023-07850-z","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T08:01:40Z","timestamp":1686297700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7139-3102","authenticated-orcid":false,"given":"Robert B.","family":"Hines","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Schoborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Sumner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Elgin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunpu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"7850_CR1","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andre","year":"2004","unstructured":"Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, Multicenter International Study of Oxaliplatin\/5-Fluorouracil\/Leucovorin in the Adjuvant Treatment of Colon Cancer I (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343\u20132351","journal-title":"N Engl J Med"},{"key":"7850_CR2","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andre","year":"2009","unstructured":"Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109\u20133116","journal-title":"J Clin Oncol"},{"key":"7850_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2011.10.019","volume":"291","author":"AS Jaggi","year":"2012","unstructured":"Jaggi AS, Singh N (2012) Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 291:1\u20139","journal-title":"Toxicology"},{"key":"7850_CR4","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/0284186X.2016.1197420","volume":"55","author":"M Stefansson","year":"2016","unstructured":"Stefansson M, Nygren P (2016) Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life. Acta Oncol 55:1227\u20131235","journal-title":"Acta Oncol"},{"key":"7850_CR5","doi-asserted-by":"crossref","first-page":"201593","DOI":"10.1155\/2011\/201593","volume":"2011","author":"A Weickhardt","year":"2011","unstructured":"Weickhardt A, Wells K, Messersmith W (2011) Oxaliplatin-induced neuropathy in colorectal cancer. J Oncol 2011:201593","journal-title":"J Oncol"},{"key":"7850_CR6","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00520-014-2255-7","volume":"22","author":"F Mols","year":"2014","unstructured":"Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L (2014) Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer 22:2261\u20132269","journal-title":"Support Care Cancer"},{"key":"7850_CR7","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2010-0248","volume":"16","author":"SB Park","year":"2011","unstructured":"Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC (2011) Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 16:708\u2013716","journal-title":"Oncologist"},{"key":"7850_CR8","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2008.19.3425","volume":"27","author":"SB Park","year":"2009","unstructured":"Park SB, Goldstein D, Lin CS, Krishnan AV, Friedlander ML, Kiernan MC (2009) Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 27:1243\u20131249","journal-title":"J Clin Oncol"},{"key":"7850_CR9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fphar.2017.00086","volume":"8","author":"N Kerckhove","year":"2017","unstructured":"Kerckhove N, Collin A, Conde S, Chaleteix C, Pezet D, Balayssac D (2017) Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol 8:86","journal-title":"Front Pharmacol"},{"key":"7850_CR10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000362668","volume":"87","author":"R Altaf","year":"2014","unstructured":"Altaf R, Lund Brixen A, Kristensen B, Nielsen SE (2014) Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer. Oncology 87:167\u2013172","journal-title":"Oncology"},{"key":"7850_CR11","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/cncr.27732","volume":"119","author":"AA Argyriou","year":"2013","unstructured":"Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, Alberti P, Bergamo F, Cortinovis D, Cazzaniga M, Santos C, Papadimitriou K, Kalofonos HP (2013) Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 119:438\u2013444","journal-title":"Cancer"},{"key":"7850_CR12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.expneurol.2011.02.019","volume":"229","author":"J Boyette-Davis","year":"2011","unstructured":"Boyette-Davis J, Dougherty PM (2011) Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline. Exp Neurol 229:353\u2013357","journal-title":"Exp Neurol"},{"key":"7850_CR13","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","volume":"32","author":"DL Hershman","year":"2014","unstructured":"Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical O (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941\u20131967","journal-title":"J Clin Oncol"},{"key":"7850_CR14","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.clcc.2016.02.009","volume":"15","author":"P Kokotis","year":"2016","unstructured":"Kokotis P, Schmelz M, Kostouros E, Karandreas N, Dimopoulos MA (2016) Oxaliplatin-induced neuropathy: a long-term clinical and neurophysiologic follow-up study. Clin Colorectal Cancer 15:e133-140","journal-title":"Clin Colorectal Cancer"},{"key":"7850_CR15","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00520-013-1766-y","volume":"21","author":"JS Gewandter","year":"2013","unstructured":"Gewandter JS, Fan L, Magnuson A, Mustian K, Peppone L, Heckler C, Hopkins J, Tejani M, Morrow GR, Mohile SG (2013) Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. Support Care Cancer 21:2059\u20132066","journal-title":"Support Care Cancer"},{"key":"7850_CR16","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1007\/s00520-013-1905-5","volume":"21","author":"C Tofthagen","year":"2013","unstructured":"Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y (2013) Oxaliplatin-induced peripheral neuropathy\u2019s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer 21:3307\u20133313","journal-title":"Support Care Cancer"},{"key":"7850_CR17","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00520-015-3063-4","volume":"24","author":"N Majithia","year":"2016","unstructured":"Majithia N, Temkin SM, Ruddy KJ, Beutler AS, Hershman DL, Loprinzi CL (2016) National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Support Care Cancer 24:1439\u20131447","journal-title":"Support Care Cancer"},{"key":"7850_CR18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00520-014-2408-8","volume":"23","author":"SH Chu","year":"2015","unstructured":"Chu SH, Lee YJ, Lee ES, Geng Y, Wang XS, Cleeland CS (2015) Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review. Support Care Cancer 23:513\u2013524","journal-title":"Support Care Cancer"},{"key":"7850_CR19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/COC.0b013e318246b50d","volume":"36","author":"LM Alejandro","year":"2013","unstructured":"Alejandro LM, Behrendt CE, Chen K, Openshaw H, Shibata S (2013) Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol 36:331\u2013337","journal-title":"Am J Clin Oncol"},{"key":"7850_CR20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3988\/jcn.2018.14.1.81","volume":"14","author":"SH Kim","year":"2018","unstructured":"Kim SH, Kim W, Kim JH, Woo MK, Baek JY, Kim SY, Chung SH, Kim HJ (2018) A prospective study of chronic oxaliplatin-induced neuropathy in patients with colon cancer: long-term outcomes and predictors of severe oxaliplatin-induced neuropathy. J Clin Neurol 14:81\u201389","journal-title":"J Clin Neurol"},{"key":"7850_CR21","unstructured":"Stedman MR, Doria-Rose P, Warren JL, Klabunde CN, MariottoA. Comorbidity technical report: the impact of different SEER-Medicare claims\u2013based comorbidity indexes on predicting non-cancer mortality for cancer patients. Obtained from: https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/comorbidity-report.pdf.\u00a0Accessed 21 Sept 2020"},{"key":"7850_CR22","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1007\/s00520-019-05063-x","volume":"28","author":"JS Gewandter","year":"2020","unstructured":"Gewandter JS, Kleckner AS, Marshall JH, Brown JS, Curtis LH, Bautista J, Dworkin RH, Kleckner IR, Kolb N, Mohile SG, Mustian KM (2020) Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data. Support Care Cancer 28:2553\u20132562","journal-title":"Support Care Cancer"},{"key":"7850_CR23","doi-asserted-by":"crossref","unstructured":"Gewandter JS, Marshall J, Brown J, Curtis LH, Dworkin RH, Kleckner I (2018) Identifying chemotherapy-induced peripheral neuropathy (CIPN) and its treatment using claims data: a URCC NCORP and NIH Collaboratory study. J Clin Oncol 36:15_suppl, e18707-e18707","DOI":"10.1200\/JCO.2018.36.15_suppl.e18707"},{"key":"7850_CR24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MLR.0b013e31815cecc3","volume":"46","author":"EB Lamont","year":"2008","unstructured":"Lamont EB, Herndon JE 2nd, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA, Cancer, Leukemia Group B (2008) Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care 46:303\u2013308","journal-title":"Med Care"},{"key":"7850_CR25","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/JOP.2013.001288","volume":"11","author":"JS Mandelblatt","year":"2015","unstructured":"Mandelblatt JS, Huang K, Makgoeng SB, Luta G, Song JX, Tallarico M, Roh JM, Munneke JR, Houlston CA, McGuckin ME, Cai L, Clarke Hillyer G, Hershman DL, Neugut AI, Isaacs C, Kushi L (2015) Preliminary development and evaluation of an algorithm to identify breast cancer chemotherapy toxicities using electronic medical records and administrative data. J Oncol Pract 11:e1-8","journal-title":"J Oncol Pract"},{"issue":"397\u2013404","key":"7850_CR26","first-page":"e391","volume":"16","author":"MJ Raphael","year":"2017","unstructured":"Raphael MJ, Fischer HD, Fung K, Austin PC, Anderson GM, Booth CM, Singh S (2017) Neurotoxicity outcomes in a population-based cohort of elderly patients treated with adjuvant oxaliplatin for colorectal cancer. Clin Colorectal Cancer 16(397\u2013404):e391","journal-title":"Clin Colorectal Cancer"},{"key":"7850_CR27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejon.2019.03.002","volume":"40","author":"N Izgu","year":"2019","unstructured":"Izgu N, Metin ZG, Karadas C, Ozdemir L, Cetin N, Demirci U (2019) Prevention of chemotherapy-induced peripheral neuropathy with classical massage in breast cancer patients receiving paclitaxel: an assessor-blinded randomized controlled trial. Eur J Oncol Nurs 40:36\u201343","journal-title":"Eur J Oncol Nurs"},{"key":"7850_CR28","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.2105\/AJPH.2013.301572","volume":"104","author":"R Hines","year":"2014","unstructured":"Hines R, Markossian T, Johnson A, Dong F, Bayakly R (2014) Geographic residency status and census tract socioeconomic status as determinants of colorectal cancer outcomes. Am J Public Health 104:e63-71","journal-title":"Am J Public Health"},{"key":"7850_CR29","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","volume":"53","author":"CN Klabunde","year":"2000","unstructured":"Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258\u20131267","journal-title":"J Clin Epidemiol"},{"key":"7850_CR30","unstructured":"Allison PD (2010) Survival analysis using SAS a practical guide, second edition. In: Editor (ed)^(eds) Book Survival analysis using SAS a practical guide, second edition. SAS Press, City"},{"key":"7850_CR31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1744-8069-7-8","volume":"7","author":"Y Mihara","year":"2011","unstructured":"Mihara Y, Egashira N, Sada H, Kawashiri T, Ushio S, Yano T, Ikesue H, Oishi R (2011) Involvement of spinal NR2B-containing NMDA receptors in oxaliplatin-induced mechanical allodynia in rats. Mol Pain 7:8","journal-title":"Mol Pain"},{"key":"7850_CR32","first-page":"179","volume":"23","author":"BY Park","year":"2010","unstructured":"Park BY, Park SH, Kim WM, Yoon MH, Lee HG (2010) Antinociceptive effect of memantine and morphine on vincristine-induced peripheral neuropathy in rats Korean. J Pain 23:179\u2013185","journal-title":"J Pain"},{"key":"7850_CR33","doi-asserted-by":"crossref","unstructured":"Salat K, Furgala-Wojas A, Salat R (2021) The microglial activation inhibitor minocycline, used alone and in combination with duloxetine, attenuates pain caused by oxaliplatin in mice. Molecules 26:1\u201327","DOI":"10.3390\/molecules26123577"},{"key":"7850_CR34","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1089\/jpm.2005.8.1118","volume":"8","author":"JR Ross","year":"2005","unstructured":"Ross JR, Goller K, Hardy J, Riley J, Broadley K, A\u2019Hern R, Williams J (2005) Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. J Palliat Med 8:1118\u20131126","journal-title":"J Palliat Med"},{"key":"7850_CR35","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1212\/01.wnl.0000249344.99671.d4","volume":"67","author":"AA Argyriou","year":"2006","unstructured":"Argyriou AA, Chroni E, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, Gourzis P, Assimakopoulos K, Kalofonos HP (2006) Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 67:2253\u20132255","journal-title":"Neurology"},{"key":"7850_CR36","doi-asserted-by":"crossref","unstructured":"Sekiguchi F, Kawabata A (2021) Role of HMGB1 in chemotherapy-induced peripheral neuropathy. Int J Mol Sci 22:1\u201318","DOI":"10.3390\/ijms22010367"},{"key":"7850_CR37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12974-019-1581-6","volume":"16","author":"M Tsubota","year":"2019","unstructured":"Tsubota M, Fukuda R, Hayashi Y, Miyazaki T, Ueda S, Yamashita R, Koike N, Sekiguchi F, Wake H, Wakatsuki S, Ujiie Y, Araki T, Nishibori M, Kawabata A (2019) Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin\/thrombomodulin system in rodents: negative impact of anticoagulants. J Neuroinflammation 16:199","journal-title":"J Neuroinflammation"},{"key":"7850_CR38","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/bph.15091","volume":"178","author":"R Tsujita","year":"2021","unstructured":"Tsujita R, Tsubota M, Sekiguchi F, Kawabata A (2021) Role of high-mobility group box 1 and its modulation by thrombomodulin\/thrombin axis in neuropathic and inflammatory pain. Br J Pharmacol 178:798\u2013812","journal-title":"Br J Pharmacol"},{"key":"7850_CR39","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3389\/fphar.2017.00344","volume":"8","author":"X Cheng","year":"2017","unstructured":"Cheng X, Huo J, Wang D, Cai X, Sun X, Lu W, Yang Y, Hu C, Wang X, Cao P (2017) Herbal medicine AC591 prevents oxaliplatin-induced peripheral neuropathy in animal model and cancer patients. Front Pharmacol 8:344","journal-title":"Front Pharmacol"},{"key":"7850_CR40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40364-016-0066-3","volume":"4","author":"A Esfahani","year":"2016","unstructured":"Esfahani A, Somi MH, Ayromlou H, Nikanfar A, Jafarabadi MA, Sadat BE, Ghoreishi Z (2016) The effect of n-3 polyunsaturated fatty acids on incidence and severity of oxaliplatin induced peripheral neuropathy: a randomized controlled trial. Biomark Res 4:13","journal-title":"Biomark Res"},{"key":"7850_CR41","first-page":"541217","volume":"2013","author":"Y Liu","year":"2013","unstructured":"Liu Y, Zhu G, Han L, Liu J, Ma T, Yu H (2013) Clinical study on the prevention of oxaliplatin-induced neurotoxicity with guilongtongluofang: results of a randomized, double-blind, placebo-controlled trial. Evid Based Complement Alternat Med 2013:541217","journal-title":"Evid Based Complement Alternat Med"},{"key":"7850_CR42","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/CAD.0b013e32832a2dc1","volume":"20","author":"P Milla","year":"2009","unstructured":"Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattel L (2009) Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics Pt-DNA adduct formation, and neurotoxicity. Anti-Cancer Drugs 20:396\u2013402","journal-title":"Anti-Cancer Drugs"},{"key":"7850_CR43","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jphs.2022.01.006","volume":"148","author":"T Miyamoto","year":"2022","unstructured":"Miyamoto T, Domoto R, Sekiguchi F, Kamaguchi R, Nishimura R, Matsuno M, Tsubota M, Fujitani M, Hatanaka S, Koizumi Y, Wang D, Nishibori M, Kawabata A (2022) Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Eeidence from clinical and preclinical studies. J Pharmacol Sci 148:315\u2013325","journal-title":"J Pharmacol Sci"},{"key":"7850_CR44","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2014.58.8533","volume":"33","author":"DR Pachman","year":"2015","unstructured":"Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, Lafky JM, Wagner-Johnston ND, Ruddy KJ, Dakhil S, Staff NP, Grothey A, Loprinzi CL (2015) Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol 33:3416\u20133422","journal-title":"J Clin Oncol"},{"key":"7850_CR45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000094376","volume":"56","author":"A Pietrangeli","year":"2006","unstructured":"Pietrangeli A, Leandri M, Terzoli E, Jandolo B, Garufi C (2006) Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 56:13\u201316","journal-title":"Eur Neurol"},{"key":"7850_CR46","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.4103\/jcrt.JCRT_971_16","volume":"14","author":"M Banach","year":"2018","unstructured":"Banach M, Zygulska AL, Krzemieniecki K (2018) Oxaliplatin treatment and peripheral nerve damage in cancer patients: a Polish cohort study. J Cancer Res Ther 14:1010\u20131013","journal-title":"J Cancer Res Ther"},{"key":"7850_CR47","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1158\/0008-5472.CAN-14-2060","volume":"74","author":"BM de Carvalho","year":"2014","unstructured":"de Carvalho BM, Kosturakis AK, Eng C, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Wang XS, Cleeland CS, Dougherty PM (2014) A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy. Cancer Res 74:5955\u20135962","journal-title":"Cancer Res"},{"key":"7850_CR48","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","volume":"25","author":"S Corbacioglu","year":"2019","unstructured":"Corbacioglu S, Jabbour EJ, Mohty M (2019) Risk factors for development of and progression of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome. Biol Blood Marrow Tr 25:1271\u20131280","journal-title":"Biol Blood Marrow Tr"},{"key":"7850_CR49","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdh095","volume":"15","author":"L Rubbia-Brandt","year":"2004","unstructured":"Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, Mentha G, Terris B (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460\u2013466","journal-title":"Ann Oncol"},{"key":"7850_CR50","doi-asserted-by":"crossref","first-page":"152882","DOI":"10.1016\/j.tox.2021.152882","volume":"460","author":"C Zhu","year":"2021","unstructured":"Zhu C, Ren X, Liu D, Zhang C (2021) Oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Toxicology 460:152882","journal-title":"Toxicology"},{"key":"7850_CR51","first-page":"e12976","volume":"28","author":"SY Hsu","year":"2019","unstructured":"Hsu SY, Huang WS, Lee SH, Chu TP, Lin YC, Lu CH, Beaton RD, Jane SW (2019) Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin-induced peripheral neuropathy in Taiwanese patients with colorectal cancer. European J Cancer Care 28:e12976","journal-title":"European J Cancer Care"},{"key":"7850_CR52","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s00520-012-1667-5","volume":"21","author":"B Vincenzi","year":"2013","unstructured":"Vincenzi B, Frezza AM, Schiavon G, Spoto C, Silvestris N, Addeo R, Catalano V, Graziano F, Santini D, Tonini G (2013) Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer 21:1313\u20131319","journal-title":"Support Care Cancer"},{"key":"7850_CR53","doi-asserted-by":"crossref","first-page":"237437352110340","DOI":"10.1177\/23743735211034028","volume":"8","author":"IK Ghabowen","year":"2021","unstructured":"Ghabowen IK, Bhandari N (2021) Concordance and patient-centered care in Medicaid enrollees\u2019 care experience with providers. J Patient Exp 8:23743735211034028","journal-title":"J Patient Exp"},{"key":"7850_CR54","doi-asserted-by":"crossref","first-page":"e9125","DOI":"10.1097\/MD.0000000000009125","volume":"96","author":"A Parikh-Patel","year":"2017","unstructured":"Parikh-Patel A, Morris CR, Kizer KW (2017) Disparities in quality of cancer care: the role of health insurance and population demographics. Medicine (Baltimore) 96:e9125","journal-title":"Medicine (Baltimore)"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07850-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07850-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07850-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T10:06:28Z","timestamp":1689329188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07850-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["7850"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07850-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2023,6,9]]},"assertion":[{"value":"8 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this was an observational study of a limited data set without any direct identifiers, this study was deemed exempt from institutional board review by the IRB at the University of Central Florida.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This study was deemed exempt from IRB review. Thus, the requirement for informed consent requirement was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"NA.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"386"}}